New CEO Appointment Signals dorsaVi’s High-Stakes Push into Robotics and AI

Leadership Change at a Critical Juncture

dorsaVi has announced the appointment of Mathew Regan as Group Chief Executive Officer, effective 1 November 2025. Regan arrives with a strong track record in scaling emerging technologies, notably reshaping Artrya Limited’s AI-driven clinical platform and securing FDA clearances. His broad expertise spans digital health, artificial intelligence, advanced manufacturing, and technology commercialisation, positioning him well to lead dorsaVi’s ambitious growth plans.

Driving Next-Generation Innovation

dorsaVi is at a pivotal stage, advancing the commercialisation of its next-generation RRAM-enabled sensor architecture and exploring applications through its Reflex platform. These innovations aim to extend the company’s reach beyond clinical and workplace monitoring into high-growth sectors such as robotics, neuromorphic computing, and edge AI. Early internal tests have demonstrated significant reductions in latency and power consumption, critical for biomedical sensing and autonomous systems.

The recent launch of Artemis Labs, dorsaVi’s innovation subsidiary, consolidates its core intellectual property and exclusive RRAM license. Artemis Labs will serve as the engine for developing advanced human–machine interface technologies, edge AI models, and robotic reflex applications, underscoring the company’s commitment to cutting-edge research and development.

Dual Leadership Model to Balance Innovation and Commercial Growth

While Regan will oversee group-wide strategy and expansion, Andrew Ronchi will remain CEO of dorsaVi’s sensor division. Ronchi’s focus will be on scaling the FDA-cleared movement analytics platform, driving U.S. sales, and integrating next-generation RRAM capabilities. This dual leadership approach aims to maintain momentum in the company’s existing commercial business while accelerating innovation in new technology platforms.

Incentives Aligned with Shareholder Value

Regan’s remuneration package includes a fixed salary of $300,000 per annum and a long-term incentive plan comprising performance rights. These rights vest based on achieving specific share price milestones within set timeframes, aligning executive rewards with shareholder returns. This structure reflects confidence in Regan’s ability to unlock commercial value from dorsaVi’s technology portfolio.

Chairman Gernot Abl expressed enthusiasm about Regan’s appointment, highlighting his proven ability to transform technology-driven businesses and unlock commercial potential. Regan himself emphasized the strategic collaborations in RRAM and the exciting opportunity to scale dorsaVi’s innovations globally.